Multiple Myeloma

Panelists discuss how bispecific T-cell–engaging therapies targeting BCMA, GPRC5D, and FcRH5 have emerged as novel immunotherapeutic approaches showing meaningful clinical activity for patients with heavily pretreated relapsed/refractory multiple

Belantamab mafodotin demonstrated benefits in overall survival in the phase 3 DREAMM-7 trial.

The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.

Outpatient models are emerging as feasible alternatives to traditional inpatient care, offering potential benefits such as reduced hospitalization, improved social well-being, and cost savings.

Panelists discuss how pharmacists can address remaining unmet needs and challenges in optimizing frontline therapy for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), including areas such as managing complex drug interactions, improving medication adherence, mitigating treatment-related toxicities, streamlining transitions of care, and enhancing patient education and support throughout the treatment journey.

Panelists discuss how they navigate challenges with payer coverage for quadruplet regimens in multiple myeloma treatment, including strategies they employ to address insurance denials or restrictions, such as providing clinical justification, leveraging recent trial data, and collaborating with financial assistance programs to ensure patients can access optimal therapy despite potential coverage difficulties.

LBL-034 could be best in class in treating individuals with multiple myeloma.

If accepted, daratumumab would be the first approved treatment for smoldering multiple myeloma.

Panelists discuss how treatment regimens for multiple myeloma patients can be personalized to improve adherence and quality of life by considering factors such as dosing schedules and routes of administration while emphasizing the role of pharmacists in providing resources and support to keep patients informed, engaged, and compliant with their individualized treatment plans.

Panelists discuss how pharmacists actively engage in educating and coordinating with nurses, oncologists, and other health care providers by conducting in-service trainings, participating in multidisciplinary team meetings, and collaborating on the development and implementation of formularies, order sets, and treatment protocols to ensure optimal patient care in multiple myeloma management.

Increased bone marrow adiposity is associated with progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.

Panelists discuss how pharmacists play a crucial role throughout the multiple myeloma patient journey, from diagnosis to treatment, by contributing to medication management, patient education, adverse effect monitoring, and the development and implementation of order sets and clinical pathways within electronic medical record systems, thereby enhancing treatment efficacy and patient safety.

Panelists discuss how subcutaneous (SC) administration of drugs like daratumumab offers advantages over intravenous (IV) administration in terms of reduced health care resource utilization, improved patient convenience, and potentially better treatment adherence, while also considering potential drawbacks such as injection site reactions and the need for proper training in SC administration techniques.

These therapies are being investigated in earlier lines, with several new treatments in development.

Dispensing, communicating, and recording information may look different at each center.

The tool can detect cell changes and mutations that drive resistance and relapse.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.

Small molecule agents continue to be beneficial additions to multiple myeloma treatment, even with the development of T-cell redirected therapies.

These interim trial results support the ongoing phase 3 ITHACA trial.

Experts discuss emerging targets in the immunotherapy landscape and how to improve patient outcomes through innovative approaches.

Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management.

The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Ashraf Badros, MBCHB, discussed findings from the AURIGA study being presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.